Fate Therapeutics (FATE) Total Liabilities (2012 - 2026)

Fate Therapeutics has reported Total Liabilities for 15 years, with the latest figure at $105.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 4.58% year-over-year to $105.2 million; the trailing twelve-month figure through Mar 2026 stood at $105.2 million (down 4.58% YoY), and the FY2025 full-year result was $111.8 million, down 8.38% from the prior year.
• Total Liabilities for Q1 2026 stood at $105.2 million, down from $111.8 million in the prior quarter.
• The five-year high for Total Liabilities was $231.3 million in Q3 2022, with the low at $105.2 million in Q1 2026.
• Historically, Total Liabilities has averaged $150.6 million across 5 years, with a median of $137.8 million in 2023.
• Annual changes were most pronounced in 2023 — Total Liabilities slumped 39.05% — and 2026, when it slipped 4.58%.
• Fate Therapeutics' Total Liabilities stood at $221.6 million in 2022, then tumbled by 37.82% to $137.8 million in 2023, then declined by 11.49% to $122.0 million in 2024, then declined by 8.38% to $111.8 million in 2025, then slipped by 5.86% to $105.2 million in 2026.
• The last three Total Liabilities figures came in at $105.2 million (Q1 2026), $111.8 million (Q4 2025), and $109.6 million (Q3 2025), per Business Quant data.